Optimization Therapy by Coupling Intermittent Androgen Suppression with Impulsive Chemotherapy for a Prostate Cancer...

Area of Science:

• Oncology
• Mathematical Modeling
• Pharmacology

Background:

• Prostate cancer often relapses during intermittent androgen suppression due to rising prostate-specific antigen (PSA).
• Chemotherapy, while historically limited, shows promise in advanced prostate cancer, especially with new agents.
• Combining intermittent androgen suppression with pulsed chemotherapy is a key clinical strategy.

Purpose of the Study:

• To model the transformation mechanism of three cancer cell types under intermittent androgen suppression and chemotherapy.
• To incorporate the residual effect of chemotherapy in suppressing cancer cell production and preventing relapse.
• To determine optimal treatment durations, dosages, and strategies for different patient types to inhibit prostate cancer relapse.

Main Methods:

• Development of a mathematical model to describe cancer cell transformation and treatment effects.
• Extension of the model to include the residual impact of chemotherapy.
• Application of an optimal algorithm and numerical simulations to identify optimal treatment parameters and strategies.
• Comparison of PSA levels with and without the residual effect of chemotherapy.

Main Results:

• Optimal intermittent androgen suppression with alterable cycles is crucial for Type I and II patients, reducing treatment time and PSA levels.
• Optimal hybrid schedules successfully prevent relapse in Type II and III patients.
• Simulations demonstrate the model's validity in reducing PSA and chemotherapy dosages, highlighting the importance of chemotherapy's residual effect.

Conclusions:

• Tailored intermittent androgen suppression and chemotherapy regimens are vital for effective prostate cancer management.
• The proposed modeling approach and algorithms offer a valid method for optimizing treatment strategies and minimizing PSA levels.
• Hybrid treatment schedules show significant potential in averting prostate cancer relapse, particularly for advanced disease stages.